Harry Snyder

• Lecturer, Health Policy and Management

https://publichealth.berkeley.edu/people/harry-snyder/

Consequently diabetes diet for indian generic glycomet 500 mg, rather than attempting to structure this presentation around representative drugs diabetes symptoms numbness in feet buy glycomet with mastercard, we discuss the actions of the adrenergic agonists one receptor at a time blood glucose homeostasis 500 mg glycomet order fast delivery. Our discussion begins with alpha1 receptors diabetes mellitus in dogs ppt purchase glycomet overnight delivery, and then moves to alpha2 receptors diabetes symptoms after eating glycomet 500 mg purchase visa, beta1 receptors, beta2 receptors, and finally dopamine receptors. For each receptor type, we discuss both the therapeutic and adverse responses that can result from receptor activation. To understand the effects of any specific adrenergic agonist, all you need is two types of information: (1) the identity of the receptor(s) at which the drug acts and (2) the effects produced by activating those receptors. This is the same approach to understanding neuropharmacologic agents that we discussed in Chapter 12. We are about to discuss the clinical consequences of adrenergic receptor activation, and Table 13­3 shows the responses to activation of those receptors. If you choose not to memorize Table 13­3 now, be prepared to refer back to it as we discuss the consequences of receptor activation. Of the two, vasoconstriction is the one for which alpha1 agonists are used most often. Clinical Consequences of Alpha1 Activation In this section we discuss the therapeutic and adverse effects that can result from activation of alpha1-adrenergic receptors. Therapeutic Applications of Alpha1 Activation Activation of alpha1 receptors elicits two responses that can be of therapeutic use: (1) vasoconstriction (in blood vessels Hemostasis. Hemostasis is defined as the arrest of bleeding, which alpha1 agonists support through vasoconstriction. Alpha1 stimulants are given to stop bleeding primarily in the skin and mucous membranes. Nasal congestion results from dilation and engorgement of blood vessels in the nasal mucosa. Specific alpha1-activating agents employed as nasal decongestants include phenylephrine (administered topically) and pseudoephedrine (administered orally). Alpha1 agonists are frequently combined with local anesthetics to delay systemic absorption. Because keeping the drug at the local site of action prolongs anesthesia, allows a reduction in anesthetic dosage, and reduces the systemic effects that a local anesthetic might produce. Because of their ability to cause vasoconstriction, alpha1 agonists can elevate blood pressure in hypotensive patients. Please note, however, that alpha1 agonists are not the primary therapy for hypotension. Rather, they are reserved for situations in which fluid replacement and other measures either are contraindicated or have failed to restore blood pressure to a satisfactory level. Activation of alpha1 receptors on the radial muscle of the iris causes mydriasis (dilation of the pupil), which can facilitate eye examinations and ocular surgery. Note that producing mydriasis is the only clinical use of alpha1 activation that is not based on vasoconstriction. Clinical Consequences of Beta1 Activation All of the clinically relevant responses to activation of beta1 receptors result from activating beta1 receptors in the heart; activation of renal beta1 receptors is not associated with either beneficial or adverse effects. Adverse Effects of Alpha1 Activation All of the adverse effects caused by alpha1 activation result directly or indirectly from vasoconstriction. The cause is lack of blood flow to the affected area secondary to intense local vasoconstriction. If extravasation occurs, the area should be infiltrated with an alpha1-blocking agent (eg, phentolamine), which will counteract alpha1-mediated vasoconstriction, and thereby help minimize injury. The mechanism is this: Alpha1-mediated vasoconstriction elevates blood pressure, which triggers the baroreceptor reflex, causing heart rate to decline. In patients with marginal cardiac reserve, the decrease in cardiac output may compromise tissue perfusion. Heart failure is characterized by a reduction in the force of myocardial contraction, resulting in insufficient cardiac output. Because activation of beta1 receptors in the heart has a positive inotropic effect (ie, increases the force of contraction), drugs that activate these receptors can improve cardiac performance. This condition is characterized by profound hypotension and greatly reduced tissue perfusion. By increasing heart rate and force of contraction, beta1 stimulants can increase cardiac output and can thereby improve tissue perfusion. By activating cardiac beta1 receptors, drugs can initiate contraction in a heart that has stopped beating. Initial management focuses on cardiopulmonary resuscitation, external pacing, or defibrillation (whichever is applicable), and identification and treatment of the underlying cause (eg, hypoxia, severe acidosis, drug overdose). Adverse Effects of Beta1 Activation All of the adverse effects of beta1 activation result from activating beta1 receptors in the heart. Overstimulation of cardiac beta1 receptors can produce tachycardia (excessive heart rate) and dysrhythmias (irregular heartbeat). In some patients, drugs that activate beta1 receptors can precipitate an attack of angina pectoris, a condition characterized by substernal pain in the region of the heart. Anginal pain occurs when cardiac oxygen supply (blood flow) is insufficient to meet cardiac oxygen needs. The most common cause of angina is coronary atherosclerosis (accumulation of lipids and other substances in coronary arteries). However, their ability to activate alpha2 receptors in the periphery has little clinical significance because there are no therapeutic applications related to activation of peripheral alpha2 receptors. Furthermore, activation of these receptors rarely causes significant adverse effects. By activating central alpha2 receptors, we can produce two useful effects: (1) reduction of sympathetic outflow to the heart and blood vessels and (2) relief of severe pain. Clinical Consequences of Beta2 Activation Applications of beta2 activation are limited to the lungs and the uterus. Drugs used for their beta2-activating ability include epinephrine, isoproterenol, and albuterol. Multiple Receptor Activation: Treatment of Anaphylactic Shock Pathophysiology of Anaphylaxis. The reaction is characterized by hypotension (from widespread vasodilation), bronchoconstriction, and edema of the glottis. Although histamine contributes to these responses, symptoms are due largely to release of other mediators (eg, leukotrienes). Anaphylaxis can be triggered by a variety of substances, including bee venom, wasp venom, latex rubber, certain foods (eg, peanuts, shellfish), and certain drugs (eg, penicillins). Benefits derive from activating three types of adrenergic receptors: alpha1, beta1, and beta2. By activating these receptors, epinephrine can reverse the most severe manifestations of the anaphylactic reaction. Activation of beta1 receptors increases cardiac output, helping elevate blood pressure. Blood pressure is also increased because epinephrine promotes alpha1-mediated vasoconstriction. In addition to increasing blood pressure, vasoconstriction helps suppress glottal edema. Individuals who are prone to severe allergic responses should carry an epinephrine auto-injector (eg, EpiPen) at all times. Antihistamines are not especially useful against anaphylaxis because histamine is only one of several contributors to the reaction. Asthma is a chronic condition characterized by inflammation and bronchoconstriction occurring in response to a variety of stimuli. Since drugs that activate beta2 receptors in the lungs promote bronchodilation, these drugs can help relieve or prevent asthma attacks. For therapy of asthma, adrenergic agonists that are selective for beta2 receptors (eg, albuterol) are preferred to less selective agents (eg, isoproterenol). This is especially true for patients who also suffer from angina pectoris or tachycardia, because drugs that can activate beta1 receptors would aggravate these cardiac disorders. It should be noted, however, that inhalation does not guarantee safety: Serious systemic toxicity can result from overdosing with inhaled sympathomimetics, so patients must be warned against inhaling too much drug. The most important adverse response to beta2 activation is hyperglycemia (elevation of blood glucose). The mechanism is activation of beta2 receptors in the liver and skeletal muscles, which promotes breakdown of glycogen into glucose. As a rule, beta2 agonists cause hyperglycemia only in patients with diabetes; in patients with normal pancreatic function, insulin release will maintain blood glucose at an appropriate level. If hyperglycemia develops in the patient with diabetes, medications used for glucose control will need to be adjusted. It occurs because activation of beta2 receptors in skeletal muscle enhances contraction. This effect can be confounding for patients with diabetes because tremor is a common symptom of hypoglycemia; however, when due to beta2 activation, it may be accompanied by hyperglycemia. Fortunately, the tremor generally fades over time and can be minimized by initiating therapy at low doses. The information is presented in the form of "drug digests" that highlight characteristic features of representative sympathomimetic agents. As noted, there are two keys to understanding individual adrenergic agonists: (1) knowledge of the receptors that the drug can activate and (2) knowledge of the therapeutic and adverse effects that receptor activation can elicit. By integrating these two types of information, you can easily predict the spectrum of effects that a particular drug can produce. Unfortunately, knowing the effects that a drug is capable of producing does not always indicate how that drug is actually used in a clinical setting. Similarly, although isoproterenol is capable of producing uterine relaxation through beta2 activation, it is no longer used for this purpose because safer drugs are available. Because receptor specificity is not always a predictor of the therapeutic applications of a particular adrenergic agonist, for each of the drugs discussed below, approved clinical applications are indicated. Clinical Consequences of Dopamine Receptor Activation Activation of peripheral dopamine receptors causes dilation of the renal vasculature. This effect is employed in the treatment of shock: by dilating renal blood vessels, we can improve renal perfusion and can thereby reduce the risk of renal failure. Therapeutic Uses Epinephrine can activate all four subtypes of adrenergic receptors. As a consequence, the drug can produce a broad spectrum of beneficial sympathomimetic effects: · Because it can cause alpha1-mediated vasoconstriction, epinephrine is used to (1) delay absorption of local anesthetics, (2) control superficial bleeding, and (3) elevate blood pressure. In the past, epinephrine-induced vasoconstriction was also used for nasal decongestion. If extravasation occurs, injury can be minimized by local injection of phentolamine, an alpha-adrenergic antagonist. By causing breakdown of glycogen secondary to activation of beta2 receptors in liver and skeletal muscle. If hyperglycemia develops, dosage adjustments will need to be made for medications used to manage diabetes. Tricyclic antidepressants block the uptake of catecholamines into adrenergic neurons. Accordingly, patients receiving a tricyclic antidepressant may require a reduction in epinephrine dosage. Several inhalation anesthetics render the myocardium hypersensitive to activation by beta1 agonists. When the heart is in this hypersensitive state, exposure to epinephrine and other beta1 agonists can cause tachydysrhythmias. Drugs that block alpha-adrenergic receptors can prevent alpha-adrenergic receptor activation by epinephrine. Alpha blockers (eg, phentolamine) can be used to treat toxicity (eg, hypertension, local vasoconstriction) caused by excessive epinephrine-induced alpha activation. Drugs that block beta-adrenergic receptors can prevent beta-adrenergic receptor activation by epinephrine. Beta-blocking agents (eg, metoprolol) can reduce adverse effects (eg, dysrhythmias, anginal pain) caused by epinephrine and other beta1 agonists. Following subQ injection, absorption is slow owing to epinephrine-induced local vasoconstriction. Epinephrine has a short half-life because of two processes: enzymatic inactivation and uptake into adrenergic nerves. Adverse Effects Because it can activate the four major adrenergic receptor subtypes, epinephrine can produce multiple adverse effects. Vasoconstriction secondary to excessive alpha1 activation can produce a dramatic increase in blood pressure. Because of the potential for severe hypertension, patients receiving parenteral epinephrine must undergo continuous cardiovascular monitoring with frequent assessment of vital signs. Because of their sensitivity to catecholamines, hyperthyroid patients are at high risk for epinephrine-induced dysrhythmias. By activating beta1 receptors in the heart, epinephrine can increase cardiac work and oxygen demand. Provocation of angina is especially likely in patients with coronary atherosclerosis. Note that solutions intended for intravenous administration are less concentrated than solutions intended for administration by most other routes, because intravenous administration of a concentrated epinephrine solution can produce potentially fatal reactions (severe dysrhythmias and hypertension). If systemic toxicity develops, epinephrine should be discontinued; if indicated, an alpha-adrenergic blocker, a beta-adrenergic blocker, or both should be given to suppress symptoms. Treatment of anaphylaxis using an epinephrine autoinjector is discussed in Box 17­1. Norepinephrine · · Receptor specificity: alpha1, alpha2, beta1 Chemical classification: catecholamine Norepinephrine [Levophed] is similar to epinephrine in several respects. Adverse effects are nearly identical to those of epinephrine: tachydysrhythmias, angina, hypertension, and local necrosis upon extravasation.

Increasing the dosage above 10 mg twice daily offers no clinical benefit diabetes insipidus test generic 500 mg glycomet visa, but will increase the risk of certain side effects test yourself diabetes symptoms quiz generic glycomet 500 mg amex. No dosage adjustment is needed in patients with renal impairment diabetes mellitus lactic acidosis generic 500 mg glycomet fast delivery, or in patients with mild or moderate hepatic impairment diabetes mellitus type 2 kngf buy 500 mg glycomet mastercard. Aripiprazole is well absorbed following oral administration diabetes bruising effective glycomet 500 mg, both in the presence and absence of food. Aripiprazole and its active metabolite-dehydro-aripiprazole-have prolonged half-lives: 75 hours and 94 hours, respectively. Because elimination is slow, (1) dosing can be done once a day and (2) about 14 days (four halflives) are required to achieve steady-state (plateau) plasma drug levels. The most common side effects are headache, agitation, nervousness, anxiety, insomnia, nausea, vomiting, dizziness, and somnolence. Although aripiprazole can block alpha1-adrenergic receptors, the incidence of orthostatic hypotension is low (1. Also, the drug has little or no effect on prolactin levels, and hence does not cause gynecomastia or galactorrhea. Like other antipsychotic drugs, aripiprazole may increase mortality in older-adult patients with dementia-related psychosis. Aripiprazole for oral therapy is available in standard tablets (2, 5, 10, 15, 20, and 30 mg) and solution (1 mg/mL), both sold as Abilify, and in orally disintegrating tablets (10 and 15 mg) sold as Abilify Discmelt. The recommended oral dosage-both initial and maintenance-is 10 or 15 mg once a day, administered with or without food. Dosages above 15 mg/day do not increase therapeutic effects, but can intensify side effects. The extended-release depot preparation [Abilify Maintena] is available in 300-mg and 400-mg doses to be given once monthly. Dosage may be increased by up to 5 mg/day, but at intervals of no less than 1 week. The initial dosage is 2 mg/day, and the usual maintenance dosage is 5 to 15 mg/day. Iloperidone is administered by mouth, and plasma levels peak 2 to 4 hours after dosing. The most common adverse effects are dry mouth, somnolence, fatigue, nasal congestion, and orthostatic hypotension, which can be severe during initial therapy. Iloperidone carries a low risk of diabetes and dyslipidemia, but can cause significant weight gain. Like other antipsychotic drugs, iloperidone may increase mortality in older-adult patients with dementia-related psychosis. Accordingly, in patients taking such inhibitors, dosage of iloperidone should be reduced. Iloperidone [Fanapt] is supplied in tablets (1, 2, 4, 6, 8, 10, and 12 mg) for oral dosing. A 4-day titration pack (2 tablets each of 1, 2, 4, and 6 mg) is available to start treatment. To minimize hypotension during initial therapy, dosage should be titrated as follows: on days 1, 2, 3, 4, 5, 6, and 7, give twice-daily doses of 1, 2, 4, 6, 8, 10, and 12 mg, respectively. Asenapine is formulated as a sublingual tablet to allow absorption directly across the oral mucosa. The drug carries a low risk of weight gain, diabetes, or dyslipidemia, and has few interactions with other agents. When asenapine is swallowed and absorbed from the intestine, it undergoes extensive first-pass metabolism, making bioavailability very low (<2%). In contrast, when the drug is administered sublingually, it gets absorbed directly across the oral mucosa, and thereby avoids first-pass metabolism. As a result, bioavailability is relatively high (about Lurasidone Actions and Therapeutic Use. In clinical trials, dosages of 20, 40, 80, and 120 mg/day were clearly superior to placebo. In clinical trials, the most common adverse events were somnolence, akathisia, parkinsonism, nausea, agitation, and anxiety. Like other antipsychotic drugs, lurasidone may increase mortality in older-adult patients with dementia-related psychosis. Lurasidone [Latuda] is supplied in tablets (20, 40, 60, 80, and 120 mg) for dosing with food (at least 350 calories). Increasing the daily dose to 120 mg does not increase benefits, but does increase the risk of dystonia and other side effects. The objective is to prevent relapse and maintain the highest possible level of functioning. As a rule, the rate of relapse is lower with depot therapy than with oral therapy. Depot preparations are valuable for all patients who need long-term treatment- not just for patients who have difficulty with adherence. Six depot preparations are currently available: haloperidol decanoate [Haldol Decanoate], fluphenazine decanoate (generic only), risperidone microspheres [Risperdal Consta], paliperidone palmitate [Invega Sustenna], aripiprazole [Abilify Maintena], and olanzapine pamoate [Zyprexa Relprevv]. Because of this slow, steady absorption, plasma levels remain relatively constant between doses. In 113 studies, clozapine was more effective than chlorpromazine in treating the core illness of schizophrenia. For example, haloperidol costs only $50 a year, risperidone costs about $2000 a year, and olanzapine costs about $4000 a year. With regard to efficacy and safety, no single agent is clearly superior to the others. For a patient who is treatment resistant, a trial with clozapine might be reasonable. Drug Selection Like all other drugs, antipsychotics should be selected on the basis of effectiveness, tolerability, and cost. Olderadult patients require relatively small doses-typically 30% to 50% of those for younger patients. During the initial phase, antipsychotics should be administered in divided daily doses. Once an effective dosage has been determined, the entire daily dose can often be given at bedtime. Since antipsychotics cause sedation, bedtime dosing helps promote sleep while decreasing daytime drowsiness. Doses used early in therapy to gain rapid control of behavior are often very high. For long-term therapy, the dosage should be reduced to the lowest effective amount. Dilution may be performed with a variety of fluids, including milk, fruit juices, and carbonated beverages. Some oral liquids are light sensitive and must be stored in amber or opaque containers. Liquid formulations of phenothiazines can cause contact dermatitis; nurses and patients should take care to avoid skin contact with these preparations. This route has the additional advantage of preventing "cheeking," since doing so will simply cause the drug to be absorbed as intended. Intramuscular injection is generally reserved for patients with severe, acute schizophrenia and for long-term maintenance. Loxapine [Adasuve] is a new formula used for acute treatment of agitation associated with schizophrenia. Accordingly, patients must be convinced to continue therapy for the entire 12-month course, even though they may be symptom free and consider themselves "cured. It is important that medication not be withdrawn at a time of stress (eg, when the patient is being discharged following hospitalization). For many patients, resumption of therapy controls symptoms and prevents further deterioration. Annual attempts should be made to lower the dosage or to discontinue treatment entirely. Long-acting (depot) antipsychotics are especially well suited for prolonged treatment. The low rate is based in large part on the widely held (but unfounded) perception that depot therapy is for patients who suffer recurrent relapse because of persistent nonadherence with oral therapy. Initial Therapy With adequate dosing, symptoms begin to resolve within 1 to 2 days. However, significant improvement takes 1 to 2 weeks, and a full response may not be seen for several months. During the first week, the goal is to reduce agitation, hostility, anxiety, and tension and to normalize patterns of sleeping and eating. The goals over this interval are increased socialization and improved self-care, mood, and formal thought processes. Of the patients who have not responded within 6 weeks, 50% are likely to respond by the end of 12 weeks. Maintenance Therapy Schizophrenia is a chronic disorder that usually requires prolonged treatment. The purpose of long-term therapy is to reduce the recurrence of acute florid episodes and to maintain the highest possible level of functioning. Following control of an acute episode, antipsychotic therapy should continue for at least 12 months. Withdrawal Adjunctive Drugs Benzodiazepines (eg, lorazepam, alprazolam) can suppress anxiety and promote sleep. In patients experiencing an acute psychotic episode, benzodiazepines can help suppress anxiety, irritability, and agitation. In addition, benzodiazepines may allow the dosage of antipsychotic medication to be reduced. Antidepressants are appropriate when schizophrenia is associated with depressive symptoms. Only one study has examined continued adjunctive use of an antidepressant with an antipsychotic medication. This tricyclic antidepressant, imipramine, was shown to be helpful in the treatment of depression. Although imipramine was successful in preventing relapse, many providers are choosing newer forms of antidepressants (serotonin/norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors), as they are thought to have fewer anticholinergic side effects. Promoting Adherence Poor adherence is a common cause of therapeutic failure, and underlies a significant proportion of hospital readmissions. Adherence can be enhanced by · Ensuring that the medication given to hospitalized patients is actually swallowed and not "cheeked. Nondrug Therapy Although drugs can be of great benefit in schizophrenia, medication alone does not constitute optimal treatment. The acutely ill patient needs care, support, and protection; a period of hospitalization may be essential. Counseling can offer the patient and family insight into the nature of schizophrenia and can facilitate adjustment and rehabilitation. Although conventional psychotherapy is of little value in reducing symptoms of schizophrenia, establishing a good therapeutic relationship can help promote adherence and can help the prescriber evaluate the patient, which in turn can facilitate dosage adjustment and drug selection. Vocational training in a sheltered environment offers the hope of productivity and some measure of independence. Ideally, the patient will be provided with a comprehensive therapeutic program to complement the benefits of medication. Schizophrenia is a chronic illness characterized by disordered thinking and reduced comprehension of reality. Negative symptoms include blunted affect, poverty of speech, and social withdrawal. Cognitive dysfunction manifests as disordered thinking, reduced ability to focus attention, plus learning and memory difficulties. Drugs in both generations increase the risk of mortality in older-adult patients with dementia-related psychosis. Therapeutic responses to antipsychotic drugs develop slowly, often taking several months to exert maximal effects. First-generation antipsychotics are thought to relieve symptoms of schizophrenia by causing strong blockade of D2 receptors. Acute dystonia and parkinsonism respond to anticholinergic drugs (eg, benztropine). Akathisia is harder to treat, but may respond to anticholinergic drugs, benzodiazepines, or beta blockers. Antipsychotic drugs can increase levels of circulating prolactin by blocking the inhibitory action of dopamine on prolactin release. Hence, regular blood tests are mandatory and the drug should be reserved for patients who have not responded to other antipsychotics. Antipsychotic depot preparations (eg, haloperidol decanoate, fluphenazine decanoate) are used for long-term maintenance therapy of schizophrenia. Preadministration Assessment Therapeutic Goal Treatment of schizophrenia has three goals: suppression of acute episodes, prevention of acute exacerbations, and maintenance of the highest possible level of functioning. Baseline Data Patients should receive a thorough mental status examination and a physical examination. Observe and record such factors as overt behavior (eg, gait, pacing, restlessness, volatile outbursts), emotional state (eg, depression, agitation, mania), intellectual function (eg, stream of thought, coherence, hallucinations, delusions), and responsiveness to the environment. Determine vital signs and obtain complete blood counts, electrolytes, and evaluations of hepatic, renal, and cardiovascular function. Use with caution in patients with glaucoma, adynamic ileus, prostatic hypertrophy, cardiovascular disease, hepatic or renal dysfunction, and seizure disorders.

Cheap glycomet 500 mg on-line. How Adam Reversed Type 2 Diabetes.

A summary of nursing implications for anticho- Vocational training in a sheltered environment offers the hope of productivity and some measure of independence metabolic disease questions cheap glycomet 500 mg buy on-line. Ongoing Evaluation and Interventions Evaluating Therapeutic Effects Success is indicated by improvement in psychotic symptoms diabetes type 1 patient uk cheap glycomet 500 mg visa. Evaluate for suppression of hallucinations diabetes hypertension medications cheap glycomet online, delusions blood sugar monitor iphone buy glycomet uk, agitation managing diabetes journal articles buy glycomet 500 mg mastercard, tension, and hostility, and for improvement in judgment, insight, motivation, affect, self-care, social skills, anxiety management, and patterns of sleeping and eating. In hospitalized patients, measure blood pressure and pulses before dosing and 1 hour after. Make these measurements while the patient is lying down and again after he or she has been sitting or standing for 1 to 2 minutes. Sedation is most intense during the first weeks of therapy and declines with continued drug use. Warn patients about sedative effects, and advise them to avoid hazardous activity until sedation subsides. Inform patients about signs of hypotension (lightheadedness, dizziness) and advise them to sit or lie down if these occur. Inform patients that hypotension can be minimized by moving slowly when standing up. Orthostatic hypotension is most likely with linergic effects is given in Chapter 14. These reactions develop within hours to months dystonia and parkinsonism respond to anticholinergic drugs (eg, benztropine). Akathisia may respond to anticholinergic drugs, beta blockers, or benzodiazepines. Inform patients and their families about their families about symptoms (eg, muscle spasm of tongue, face, neck, or back; tremor; rigidity; restless movement), and instruct them to notify the prescriber if these appear. Acute Although there is no reliable treatment, the following measures are recommended: discontinue all anticholinergic drugs; give a benzodiazepine; and discontinue the early signs (eg, fine, worm-like movements of the tongue), and instruct them to notify the prescriber if these develop. Neuroleptics reduce seizure threshold, thereby increasing the risk of seizures, especially in patients with epilepsy and other seizure disorders. For patients with seizure disorders, adequate doses of antiseizure medication must be employed. Monitor the patient for seizure activity; if loss of seizure control occurs, dosage of antiseizure medication must be increased. Counsel patients about possible sexual dysfunction and encourage them to report problems. Inform patients that phenothiazines can sensitize the skin to ultraviolet light, thereby increasing the risk of sunburn. Advise them to avoid excessive exposure to sunlight, apply a sunscreen, and wear protective clothing. Agents to avoid include tricyclic antidepressants, thioridazine, several antidysrhythmic drugs (eg, amiodarone, dofetilide, quinidine), and certain antibiotics (eg, clarithromycin, erythromycin, moxifloxacin). If blood tests indicate Antipsychotics can promote growth of prolactindependent carcinoma of the breast and must not be used by patients with this cancer. Preadministration Assessment Therapeutic Goal See First-Generation (Conventional) Antipsychotics. Also, obtain baseline measurements of weight, waist circumference, fasting blood glucose, and fasting lipid levels. Clozapine is contraindicated for patients with a history of bone marrow depression or clozapine-induced agranulocytosis, and for those taking myelosuppressive drugs (eg, many anticancer drugs). Use asenapine, iloperidone, quetiapine, and paliperidone with caution in these patients. Symptoms include tremor, agitation, sleepiness, difficulty feeding, severe breathing difficulty, and altered muscle tone (increased or decreased). Advise patients who become pregnant not to their medication without consulting the Death in Older-Adult Dementia Patients. Warn patients patients to avoid all drugs with anticholinergic properties, including the antihistamines and certain over-the-counter sleep aids. Implementation: Measures to Enhance Therapeutic Effects Promoting Adherence See First-Generation (Conventional) Antipsychotics. Ongoing Evaluation and Interventions Evaluating Therapeutic Effects See First-Generation (Conventional) Antipsychotics. Clozapine produces agranulocytosis in 1% to 2% of patients, typically during the first 6 months of treatment. Additional testing may be completed when considering the possibility of neutropenia, when adding other antipsychotics, or when clinically indicated. When subsequent daily monitoring indicates that cell counts have risen above these values, clozapine can be resumed. To monitor weight gain, determine weight at baseline and every 3 months thereafter. Inform patients about the risk of weight gain and with a combination of diet, exercise, and metformin. To monitor for diabetes, measure fasting blood glucose at baseline, 12 weeks later, and annually thereafter. In patients with documented diabetes at baseline, monitor for worsening of glucose control. Inform all patients about symptoms of diabetes-hyperglycemia, polyuria, polydipsia, polyphagia, dehydration-and instruct them to tell the prescriber if they occur. If diabetes develops, it can be managed encourage them to control caloric intake and get regular exercise. If significant weight gain occurs, it can be managed with insulin or an oral antidiabetic drug (eg, metformin). To monitor for dyslipidemia, obtain a fasting lipid profile at baseline and every 6 months thereafter. Warn patients against driving and other hazardous activities if seizures have occurred. Warn patients against Warn patients about the risk of agranulocytosis, and inform them that clozapine will not be dispensed without repeated proof of blood counts. Inform patients about early signs of infection (fever, sore throat, fatigue, mucous membrane ulceration), and instruct them to report these immediately. Olanzapine and ziprasidone can cause leukopenia/neutropenia, and can thereby increase the risk of infection. Advise women who become pregnant not to disDeath in Older-Adult Dementia Patients. Inform patients about signs and symptoms (eg, unexplained fatigue, dyspnea, tachypnea, chest pain, palpitations), and advise them to seek immediate medical attention if these develop. Clozapine must not be given to patients taking other drugs that can suppress bone marrow function (eg, many anticancer agents). Unfortunately, depression is underdiagnosed and undertreated: Although 50% of depressed individuals seek help, only 20% receive adequate treatment. This is especially sad in that treatment can help many people: About 30% of those given antidepressants achieve full remission; another 20% to 30% achieve at least a 50% reduction in symptom severity. Associated symptoms include insomnia (or sometimes hypersomnia); anorexia and weight loss (or sometimes hyperphagia and weight gain); mental slowing and loss of concentration; feelings of guilt, worthlessness, and helplessness; thoughts of death and suicide; and overt suicidal behavior. For a diagnosis to be made, symptoms must be present most of the day, nearly every day, for at least 2 weeks. It is important to distinguish between major depression and normal grief or sadness. Rather, grief and sadness are appropriate reactions to a major life stressor (eg, death of a loved one, loss of a job). In most cases, grief and sadness resolve spontaneously over several weeks and do not require medical intervention. However, if symptoms are unusually intense, and if they fail to resolve within an appropriate time, a major depressive episode may have been superimposed. Pathogenesis the etiology of major depression is complex and incompletely understood. For some individuals, depression seems to descend "out of the blue"; otherwise healthy people- unexpectedly and without apparent cause-find themselves feeling profoundly depressed. For many others, depressive episodes are brought on by stressful life events, such as bereavement, loss of a job, or childbirth (Box 32­1). Since depression does not occur in everyone, it would appear that some people are more vulnerable than others. Factors that may contribute to vulnerability include genetic heritage, a difficult childhood, and chronic low self-esteem. Clinical observations made in the 1960s led to formulation of the monoamine-deficiency hypothesis of depression, which asserts that depression is caused by a functional deficiency of monoamine neurotransmitters (norepinephrine, serotonin, or both). Findings that support the hypothesis include (1) induction of depression with reserpine, a drug that depletes monoamines from the brain; (2) induction of depression with inhibitors of tyrosine hydroxylase, an enzyme needed for Our principal focus in this chapter is drugs used to treat major depression. For most, the symptoms are mild and transient, reflecting a condition sometimes called the "baby blues. An estimated 60% to 70% of women experience depression post partum, and in 50% of these depression begins before delivery-hence the term peripartum depression. Symptoms include tearfulness, sadness, nervousness, irritability, and anxiety, along with difficulty eating and sleeping. Her self-esteem and selfconfidence may decline, and she may feel unqualified to care for her baby. Fortunately, all of these symptoms pass quickly: They develop a few days after delivery and are gone by day 10. Left untreated, peripartum depression lasts for months and is likely to become worse as time passes. The condition is detrimental to the mother, and it can adversely affect the child, preventing secure attachment and impairing cognitive, emotional, and behavioral development. Otherwise, the diagnostic criteria are the same as for all other episodes of major depression. However, most clinicians who study the disorder use a different criterion: To them, depression is considered postpartum if it begins within 3 months of delivery-not just within 4 weeks. In addition to a prior history of the disorder, risk factors include a history of depression unrelated to childbirth, history of premenstrual dysphoric disorder (ie, severe premenstrual syndrome), and major stress related to family, work, or residence (eg, death of a loved one, loss of a job, moving away from a familiar town or city). The underlying cause of peripartum depression is unknown, but several factors are thought to contribute. Heading the list is the sharp drop in estrogen and progesterone levels that occurs after delivery. Caring for a baby, who needs round-the-clock attention and feeding, exacerbates tiredness and exhaustion. Feelings of loss are common: Women experience loss of freedom, loss of control, and even loss of identity. Stress increases substantially, owing to increased workload and responsibilities, coupled with feelings of selfdoubt and inadequacy, and compounded by a self-imposed (albeit highly unrealistic) expectation to be a "perfect" parent. Thyroid insufficiency may also contribute: Levels of thyroid hormone often decline after delivery, causing symptoms that can mimic depression. Accordingly, thyroid levels should be checked and, if indicated, replacement therapy should be implemented. Screening for peripartum depression should be contemplated in all women, although evidence is lacking regarding universal screening. Screening can be accomplished with a quick test: the Edinburgh Postnatal Depression Scale. Treatment of peripartum depression is much like treatment of major depression unrelated to pregnancy. The principal treatment modalities are psychotherapy and antidepressant drugs, both of which can be effective. Other beneficial measures include joining a support group for new mothers and recruiting family members and friends to assist with household and baby-related chores. Although antidepressants are clearly appropriate, there are few published data to guide selection. However, if a woman has responded to an antidepressant from a different class in the past, that drug should be tried first. To minimize side effects, dosage should be low initially (50% of the usual starting dosage) and then gradually increased. To reduce the risk of relapse, treatment should continue for at least 6 months after symptoms have resolved. Unfortunately, even then the relapse rate is high: Between 50% and 85% of patients experience at least one more depressive episode. All of these drugs can be detected in breast milk-but levels of some are lower (safer) than levels of others. Studies show that drug activity in breast-fed infants is extremely low, and no adverse reactions have been observed. Infants of breast-feeding mothers on antidepressants should be monitored closely for these side effects. Although these observations lend support to the monoamine-deficiency hypothesis, it is clear that the hypothesis is too simplistic. However, despite its shortcomings, the monoamine-deficiency hypothesis does provide a useful conceptual framework for understanding antidepressant drugs. Treatment Overview Depression can be treated with three major modalities: (1) pharmacotherapy, (2) depression-specific psychotherapy (eg, cognitive behavioral therapy or interpersonal psychotherapy), and (3) somatic therapies, such as electroconvulsive therapy and transcranial magnetic stimulation. For patients with mild to moderate depression, drug therapy and psychotherapy can be equally effective. For those with more severe depression, a combination of drug therapy and psychotherapy is better than either intervention alone. Electroconvulsive therapy can be used when a rapid response is needed, or when drugs and psychotherapy have not worked. All of these classes are equally effective, as are the individual drugs within each class. Hence, differences among these drugs relate mainly to side effects and drug interactions.

During the first few weeks of therapy patients lose weight diabetic diet daily carb intake discount glycomet 500 mg mastercard, perhaps because of drug-induced nausea and vomiting diabetes treatment kolkata discount glycomet 500 mg buy online. Symptoms include dizziness diabetes medications in liver disease order 500 mg glycomet fast delivery, headache diabetes 2 prevention glycomet 500 mg purchase free shipping, nausea diabetes diet for vegetarian discount glycomet amex, sensory disturbances, tremor, anxiety, and dysphoria. These begin within days to weeks of the last dose, and then persist for 1 to 3 weeks. Because fluoxetine has a prolonged half-life, plasma levels decline slowly when dosing is stopped. The syndrome can be managed with supportive care and generally abates within a few days. This is much less frequent than among patients taking antipsychotic medications (see Chapter 31). However, since bruxism usually occurs during sleep, the condition often goes unrecognized. Sequelae of bruxism include headache, jaw pain, and dental problems (eg, cracked fillings). One theory is that they inhibit release of dopamine, a neurotransmitter that suppresses activity in certain muscles, including those of the jaw. Other options include switching to a different class of antidepressant, use of a mouth guard, and treatment with low-dose buspirone (5 to 10 mg 1 to 3 times a day). Fluoxetine can cause hyponatremia (serum sodium below 135 mEq/L), probably by increasing secretion of antidiuretic hormone. Accordingly, when fluoxetine is used in older-adult patients, sodium should be measured at baseline and periodically thereafter. Fluoxetine may cause dizziness and fatigue; patients who experience intense dizziness and fatigue should be warned against driving and other hazardous activities. Skin rash, which can be severe, has occurred in 4% of patients; in most cases, rashes readily respond to drug therapy (antihistamines, glucocorticoids) or to withdrawal of fluoxetine. The risk of antidepressant-induced suicide is greatest among children, adolescents, and young adults. Patients starting treatment or changing doses must be monitored closely for suicidal behavior. Fluoxetine is available in several oral formulations and is sold under four trade names: Prozac, Prozac Weekly, Sarafem, and Selfemra. However, doses greater than 20 mg/day may increase adverse effects without increasing benefits. For older-adult patients and patients with impaired liver function, the dosage should be low initially and then cautiously increased if needed. Patients who have been treated successfully with 20 mg of fluoxetine daily for at least 13 weeks can be switched to onceweekly dosing (using 90-mg delayed-release capsules) for maintenance. Sertraline is indicated for major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder (social phobia). The drug is used off-label to treat generalized anxiety disorder, impulse control disorders, mild dementia-associated agitation in nonpsychotic patients, eating disorders, and paraphilia. In the blood, the drug is highly bound Meperidine [Demerol] Methadone [Dolophine] Tramadol [Ultram] Triptan Antimigraine Drugs Almotriptan [Axert] Eletriptan [Relpax] Frovatriptan [Frova] Rizatriptan [Maxalt] Sumatriptan [Imitrex] Zolmitriptan [Zomig] Others St. The risk of bleeding with warfarin is compounded by a pharmacokinetic interaction. Because fluoxetine is highly bound to plasma proteins, it can displace other highly bound drugs. Sertraline undergoes extensive hepatic metabolism followed by elimination in the urine and feces. Common side effects include headache, tremor, insomnia, agitation, nervousness, nausea, diarrhea, weight gain, and sexual dysfunction. Because of a risk of pimozide-induced dysrhythmias, sertraline (which raises pimozide levels) and pimozide should not be combined. Sertraline is available in tablets (25, 50, and 100 mg) and a concentrated oral solution (20 mg/mL). For treatment of depression, the initial adult daily dosage is 50 mg, administered in the morning or evening. After 4 to 8 weeks, the dosage may be increased by 50-mg increments to a maximum of 200 mg/ day. Like all other antidepressants, paroxetine may increase the risk of suicide, especially in children and young adults. Paroxetine is available as two salts: paroxetine hydrochloride and paroxetine mesylate. Although the two preparations have not been compared directly, effects are likely to be identical. The drug is approved for obsessive-compulsive disorder and social anxiety disorder. Unlabeled uses include major depression, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and bulimia nervosa. The drug undergoes extensive hepatic metabolism followed by excretion in the urine. Common side effects include nausea, vomiting, dry mouth, headache, constipation, weight gain, and sexual dysfunction. Accordingly, liver function should be assessed before treatment and weekly during the first month of therapy. Unlabeled uses include panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder. The drug undergoes hepatic metabolism followed by excretion in the urine and feces. The most common adverse effects are nausea, somnolence, dry mouth, and sexual dysfunction. Citalopram enters breast milk in amounts sufficient to cause somnolence, reduced feeding, and weight loss in the infant. Like all other antidepressants, citalopram may increase the risk of suicide, especially in children and young adults. Citalopram [Celexa] is available in tablets (10, 20, and 40 mg) and an oral solution (10 mg/5 mL). Dosage may be increased slowly to a maximum of 40 mg/day in patients younger than 60 years. Doses above 40 mg/day offer no increase in benefits, but do increase the risk of dysrhythmias and other adverse effects. The drug is indicated for major depression, obsessive-compulsive disorder, social anxiety disorder, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and postmenopausal vasomotor symptoms (hot flashes). Paroxetine is used off-label to treat bipolar disorder, eating disorders, impulse control disorders, obsessive-compulsive disorder in children, mild dementia-associated agitation in nonpsychotic patients, and paraphilia. Paroxetine is well absorbed following oral administration, even in the presence of food. After 5 to 6 weeks, the major complaints are headache, weight gain, and sexual dysfunction. Food and Drug Escitalopram Escitalopram [Lexapro, Cipralex] is the S-isomer of citalopram [Celexa], which is a 50: 50 mixture of S- and R-isomers. Accordingly, escitalopram retains the therapeutic benefits of citalopram, but may be better tolerated. Escitalopram is approved for major depression and generalized anxiety disorder, and has additional indication for treatment of obsessive-compulsive disorder in Canada. In clinical trials, the most common side effects were nausea, insomnia, somnolence, sweating, and fatigue. However, the true incidence of sexual dysfunction may be higher because the incidence of sexual problems reported during clinical trials is usually considerably lower than the incidence seen in actual practice. Symptoms, which can be managed with supportive care, generally abate within a few days. Symptoms include anxiety, agitation, tremors, headache, vertigo, nausea, tachycardia, and tinnitus. However, dosages as large as 375 mg/day have been used for severely depressed patients. Dosage should be reduced in patients with liver disease, and possibly in those with kidney disease. As with all other antidepressants, dosage should be tapered slowly when treatment is stopped. Escitalopram [Lexapro, Cipralex] is available in tablets (5, 10, and 20 mg) and an oral solution (5 mg/5 mL). The recommended initial dosage is 10 mg/day, taken in the morning or evening, with or without food. In clinical trials, dosages above 10 mg/day did not increase antidepressant effects, but did intensify side effects. There is no need to reduce the dosage in olderadult patients or in patients with either hepatic impairment or mild to moderate renal impairment. However, in patients with severe renal impairment, a dosage reduction may be required. Antidepressants may increase the risk of suicide, especially during the early phase of treatment. Children/ adolescents Pregnant women Breast-feeding women Older adults Desvenlafaxine Desvenlafaxine [Pristiq], approved in 2008, is the major active metabolite of venlafaxine. At this time, desvenlafaxine is approved only for major depression, in contrast to venlafaxine, which is approved for major depression, generalized anxiety disorder, panic disorder, and social phobia. Desvenlafaxine is well absorbed following oral administration, both in the presence and absence of food. The drug undergoes some hepatic metabolism, and is excreted in the urine as metabolites and parent drug. The most common are nausea, headache, dizziness, insomnia, diarrhea, dry mouth, sweating, and constipation. Like all other antidepressants, desvenlafaxine may increase the risk of suicide in children and young adults. Some neonates exposed to the drug in utero have required prolonged hospitalization, respiratory support, and tube feeding. Additional concerns include hyponatremia, sustained hypertension, serotonin syndrome, bleeding, seizures, and withdrawal symptoms if the drug is discontinued abruptly. As with venlafaxine, combining desvenlafaxine with another serotonergic drug increases the risk of serotonin syndrome. The recommended dosage is 50 mg once daily, taken with or without food, about the same time each day. Increasing the dose above 50 mg/day offers no therapeutic benefit, but does increase the risk of side effects. In patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dosage should be reduced to 50 mg every other day. There is no need to reduce the dosage in patients with moderate renal impairment or in those with liver impairment of any degree. To minimize withdrawal reactions, the drug should be discontinued slowly (by gradually increasing the dosing interval). Venlafaxine does not block cholinergic, histaminergic, or alpha1-adrenergic receptors. Venlafaxine is well absorbed following oral administration, both in the presence and absence of food. In the liver, much of each dose is converted to desvenlafaxine, an active metabolite. The half-life is 5 hours for the parent drug and 11 hours for the active metabolite. The most common is nausea (37% to 58%), followed by headache, anorexia, nervousness, sweating, somnolence, and insomnia. Venlafaxine can also cause dose-related sustained diastolic hypertension; blood pressure should be monitored. Some patients experience sustained mydriasis (dilation of the pupil), which can increase the risk of eye injury in those with elevated intraocular pressure or glaucoma. Like all other antidepressants, venlafaxine may increase the risk of suicide, especially in children and young adults. Clinical trials have shown that duloxetine is clearly superior to placebo: Treatment reduces depressive symptoms and may also reduce physical pain associated with depression (eg, backache). Furthermore, benefits may develop quickly, in some cases within 2 weeks of starting treatment. There does not not appear to be any difference in efficacy when treating depression with duloxetine. In addition, duloxetine seems less well tolerated than the other medications commonly used to treat depression. As a result, there is no basis for choosing duloxetine over other antidepressants. In addition to its use in depression, duloxetine is approved for fibromyalgia, generalized anxiety disorder, pain of diabetic peripheral neuropathy, and chronic musculoskeletal pain, including low back pain and pain from osteoarthritis. The drug is used off-label for stress urinary incontinence (in contrast to urge urinary incontinence). In patients with severe renal impairment, levels of duloxetine and its metabolites are greatly increased, and in those with severe hepatic impairment, the half-life is greatly prolonged. Accordingly, duloxetine is not recommended for patients with severe renal or hepatic dysfunction. In clinical trials, the most common adverse effects were nausea, dry mouth, insomnia, somnolence, constipation, reduced appetite, fatigue, increased sweating, and blurred vision. Duloxetine can cause a small increase in blood pressure, and hence blood pressure should be measured at baseline and periodically thereafter.

References

• Morse SA, Zhang R, Thakur V, et al: Hypertension and the metabolic syndrome, Am J Med Sci 330:303n310, 2005.
• Stassen NA, Lukan JK, Spain DA, et al. Reevaluation of diagnostic procedures for transmediastinal gunshot wounds. J Trauma. 2002;53(4):635- 638; discussion 638.
• Hoeper MM. Treating pulmonary hypertension in COPD: where do we start. Eur Respir J 2008;32:541-2.
• Simmons OP, Manson PN. Endoscopic management of orbital and frontal sinus fractures. Craniomaxillofac Trauma Reconstr 2009;2:177-184.